Entries of Ziepert, Marita on the publication server

Kosch, Robin, Limm, Katharina, Staiger, Annette M., Kurz, Nadine S., Seifert, Nicole, Oláh, Bence, Solbrig, Stefan , Poeschel, Viola, Held, Gerhard, Ziepert, Marita, Schmitz, Norbert, Chteinberg, Emil, Siebert, Reiner, Spang, Rainer , Zacharias, Helena U., Ott, German, Oefner, Peter J. and Altenbuchinger, Michael (2025) Integration of high-throughput proteomic data and complementary omics layers with PriOmics. Genome Research, gr.279487.124. Fulltext not available.

Houot, Roch, Poeschel, Viola, Altmann, Bettina, Angel, Stephanie, Thurner, Lorenz, Illmer, Thomas, Andre, Marc, Dreyling, Martin, Maisonneuve, Hervé, Tilly, Hervé, Mayer, Stephanie, Casasnovas, Olivier , Le Gouill, Steven, Offner, Fritz, Cartron, Guillaume, Kerkhoff, Andrea, Weber, Thomas, Hoffmann, Joerg, Ziepert, Marita, Klapper, Wolfram, Itti, Emmanuel, Hellwig, Dirk , Natchkebia, Giorgi, de Leval, Laurence, Rosenwald, Andreas, Haioun, Corinne, Dercle, Laurent, Gaulard, Philippe and Held, Gerhard (2022) Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere 6 (2), e672. Fulltext not available.

Nordmo, Carmen, Glehr, Gunther, Altenbuchinger, Michael, Spang, Rainer, Ziepert, Marita, Horn, Heike, Staiger, Annette M., Ott, German, Schmitz, Norbert, Held, Gerhard, Einsele, Hermann, Topp, Max, Rosenwald, Andreas and Rauert-Wunderlich, Hilka (2021) Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leukemia & Lymphoma 62 (5), pp. 1107-1115. Fulltext not available.

Kaddu-Mulindwa, Dominic , Altmann, Bettina, Held, Gerhard, Angel, Stephanie, Stilgenbauer, Stephan, Thurner, Lorenz, Bewarder, Moritz, Schwier, Maren, Pfreundschuh, Michael, Löffler, Markus, Menhart, Karin , Grosse, Jirka, Ziepert, Marita, Herrmann, Ken, Dührsen, Ulrich, Hüttmann, Andreas , Barbato, Francesco, Poeschel, Viola and Hellwig, Dirk (2021) FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials. European Journal of Nuclear Medicine and Molecular Imaging 48 (11), pp. 3550-3559.

d'Amore, Francesco, Leppä, Sirpa, da Silva, Maria Gomes, Relander, Thomas, De Nully Brown, Peter, Weidmann, Eckhart, Lauritzsen, Grete Fossum, Pezzutto, Antonio, Van Hoof, Achiel, van Gelder, Michel, Doorduijn, Jeanette K, Wu, Ka Lung, Kluin-Nelemans, J.C., Lugtenburg, P.J., Jankovska, Milada, Merup, Mats, Fagerli, Unn-Merete, Walewski, Jan, Hagberg, Hans, Mariz, Jose Mario, Hansen, Per Boye, Nösslinger, Thomas, Janssens, Ann, Brandefors, Lena, Demuynck, Hilde, Schaafsma, Martyn Ronald, Christiansen, Ilse, Salek, David, Jyrkkiö, Sirkku, Prochazka, Vit, Zijlstra, Josee, Böhmer, L., Greil, Richard , Stevens, Wendy, Fijnheer, Rob, van Marwijk Kooy, Marinus, Grube, Matthias, Hopfinger, Georg, Van den Neste, Eric, Jantunen, Esa, Trümper, Lorenz, Wulf, Gerald, Altmann, Bettina, Ziepert, Marita, Loeffler, Markus and Toldbod, Helle (2012) First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy. Blood 120 (21), p. 57. Fulltext not available.

d'Amore, Francesco, da Silva, Maria Gomes, Leppa, Sirpa , Relander, Thomas, Pezzutto, Antonio, Lauritzsen, Grete F., Weidmann, Eckhart, Van Gelder, Michel, Merup, Mats, Hagberg, Hans, Fagerli, Unn-Merete, Brown, Peter de Nully, Hansen, Per Boye, Mariz, Jose Mario, Jankovska, Milada, Walewski, Jan, Doorduijn, Jeanette, Van Hoof, Achiel, Christiansen, Ilse, Jyrkkiö, Sirkku, Kluin-Nelemans, J.C., van Marwijk Kooy, Marinus, Fijnheer, Rob, Stevens, Wendy, Zijlstra, Josee, Böhmer, L., Lugtenburg, P.J., Grube, Matthias, Prochazka, Vit, Salek, David, Greil, Richard , Trümper, Lorenz, Wulf, Gerald, Altmann, Bettina, Ziepert, Marita, Loeffler, Markus, Jantunen, Esa, Hopfinger, Georg, Neste, Eric Van den and Toldbod, Helle (2011) First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,. Blood 118 (21), p. 4110. Fulltext not available.